Cargando…
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
Prevention of chemotherapy-induced nausea and vomiting (CINV) is a key component of treatment for patients with cancer. Guidelines are available to assist prescribers in the management of CINV associated with single-day chemotherapy regimens. However, currently there are no clear guidelines for mana...
Autores principales: | Affronti, Mary Lou, Bubalo, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161526/ https://www.ncbi.nlm.nih.gov/pubmed/25228819 http://dx.doi.org/10.2147/CMAR.S68102 |
Ejemplares similares
-
Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015) -
Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009) -
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009) -
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
por: Lorusso, Vito
Publicado: (2016) -
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)